Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

NCT01313689 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukaemia

Interventions

DRUG: Ofatumumab
DRUG: Physicians' Choice

Sponsor

Novartis Pharmaceuticals